Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Bristol-Myers Squibb Company

BMYMP
Current price
877.77 USD +32.77 USD (+3.88%)
Last closed 55.77 USD
ISIN US1101221083
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NYSE
Capitalization 110 170 734 592 USD
Yield for 12 month +2.84 %
1Y
3Y
5Y
10Y
15Y
BMYMP
21.11.2021 - 28.11.2021

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. Address: Route 206 & Province Line Road, Princeton, NJ, United States, 08543

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

53.23 USD

P/E ratio

Dividend Yield

4.42 %

Current Year

+45 006 000 000 USD

Last Year

+46 159 000 000 USD

Current Quarter

+11 892 000 000 USD

Last Quarter

+12 201 000 000 USD

Current Year

+34 313 000 000 USD

Last Year

+36 022 000 000 USD

Current Quarter

+8 935 000 000 USD

Last Quarter

+6 801 000 000 USD

Key Figures BMYMP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 19 455 000 576 USD
Operating Margin TTM 19.35 %
PE Ratio
Return On Assets TTM 6 %
PEG Ratio 2.1185
Return On Equity TTM -26.59 %
Wall Street Target Price 53.23 USD
Revenue TTM 47 435 001 856 USD
Book Value 8.39 USD
Revenue Per Share TTM
Dividend Share 2.4 USD
Quarterly Revenue Growth YOY 8.4 %
Dividend Yield 4.42 %
Gross Profit TTM 36 378 000 000 USD
Earnings per share -3.58 USD
Diluted Eps TTM -3.58 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY -35.8 %
Profit Margin -15.3 %

Dividend Analytics BMYMP

Champion - 10+ consecutive years of dividend increases

Dividend growth over 5 years

43 %

Continuous growth

16 years

Payout Ratio 5 years average

41 %

Dividend History BMYMP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 2.4
Ex Dividend Date 04.10.2024
Forward Annual Dividend Yield 4.42 %
Last Split Factor 1000000:95
Payout Ratio 2.26 %
Last Split Date 07.08.2001
Dividend Date 01.11.2024

Stock Valuation BMYMP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 7.837
Enterprise Value Revenue 3.2355
Price Sales TTM 2.3226
Enterprise Value EBITDA 30.2655
Price Book MRQ 6.4269

Financials BMYMP

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BMYMP

For 52 weeks

38.6 USD 56.2 USD
50 Day MA 51.23 USD
Shares Short Prior Month 21 792 101
200 Day MA 47.95 USD
Short Ratio 1.75
Shares Short 22 501 723
Short Percent 1.11 %